BIOTECHNOLOGY
Fig. 2. The history of antibody production Since the first therapeutic
mAb, muromonab-CD3, was approved by the US Food and Drug Administration (FDA), mAbs have become the predominant therapeutic modality in modern medicine. Currently, at least 579 therapeutic mAbs have been investigated, and 100 therapeutic mAbs have been approved for clinical use.
Fig. 3. Approaches for the development of therapeutic antibodies
surface. Phage display technology has been used for in vitro affinity screening for monoclonal antibody development. Single B cell antibody technology allows for the highly efficient and rapid isolation of potential mAbs. Single B cell cloning preserves the paired heavy and light chains. Single B lymphocytes can be isolated by fluorescence-conjugated antigens to determine antigen specificity. (Fig. 3) Tanks to the fast-growing gene editing and recombinant protein technologies, recombinant antibodies have no need for immunisation and can be produced in vitro via multiple organism expression systems. Te intrinsic characteristics such
as immunogenicity, binding affinity, pharmacokinetics, and specificity can also be modified easily through mutagenesis techniques. Antibody engineering techniques can alter the traditional Y shape of full-length antibodies into various types such as scFv, VHH, and Fab, which have been constructed to develop novel therapeutic drugs. Moreover, modulating recombinant antibodies can improve immune responses, such as engaging immune effector functions, developing fusion antibodies, allowing efficient tissue penetration, improving affinity against conserved targets, and increasing the half- life time in circulation.
SUMMARY Antibodies are essential molecular sentinels that are highly specific toward their corresponding antigens. Tey are widely used in life science research and as therapeutics. With the rapidly growing interest in therapeutic mAbs
in clinical studies, more and more resources are invested in the field. As a global reagent and services provider,
Sino Biological not only offers a variety of customised services, mainly focused on recombinant production of antigens and antibodies, but also provides pharmaceutical companies and biotechnology firms pre-clinical production technology services for advancing the development of mAb drug candidates.
Emma Zhao is with Sino Biological.
www.sinobiological.com
www.scientistlive.com 41
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
